Company intelligence / Profile preview

Perseus Proteomics Inc.

Tokyo, Tokyo, Japanppmx.com ↗
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

Perseus Proteomics is developing novel antibody drugs for cancer and other diseases, with a focus on utilizing proprietary antibody technologies.

Therapeutic areas
Oncology
Modalities
Antibody drugsAntibody drug conjugates
Industry
Biotech
02

Drug pipeline

7 assets

PPMX-T003

2

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Perseus Proteomics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perseus Proteomics Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call